Zogenix Doubles In Cost On Advantageous Epilepsy Drug Take A Look At Results

The drug also saw “clinically meaningful reductions” in the frequency of seizures, Zogenix said, as well as an increase in time between seizures.
Based in Emeryville, California, the pharmaceutical company expects results from a second trial in the first half of next year.
Shares of Zogenix zoomed 150 percent in premarket trading Friday after positive results from a study on its treatment of a rare form of epilepsy.
The biotechnology company reported significant results in a Phase 3 trial of its drug ZX008, which is a treatment for Dravet syndrome.
In total, 119 patients participated in the ZX008 trial.

Read more on: http://www.cnbc.com